Oregon Health and Science University Hospitals and Clinics, Portland, Oregon, USA.
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0083322. doi: 10.1128/aac.00833-22. Epub 2022 Oct 10.
The purpose of this single-center retrospective case series was to evaluate the efficacy and safety of 300-mg once-monthly intravenous (IV) pentamidine prophylaxis in 702 adult allogeneic hematopoietic stem cell transplant (HSCT) patients. We observed no cases of Pneumocystis jirovecii pneumonia (PJP) following IV pentamidine administration. Breakthrough and infections were observed in 7 (1%) and 5 (0.7%) patients, respectively. The most commonly reported adverse event was nausea. Monthly IV pentamidine is a reasonable alternative to trimethoprim-sulfamethoxazole (TMP-SMX).
本单中心回顾性病例系列研究的目的是评估 702 例异基因造血干细胞移植(HSCT)成人患者中 300mg 每月一次静脉注射(IV)戊烷脒预防的疗效和安全性。我们在 IV 戊烷脒给药后没有观察到耶氏肺孢子菌肺炎(PJP)的病例。分别有 7 例(1%)和 5 例(0.7%)患者出现突破性感染和感染。最常见的不良事件是恶心。每月一次 IV 戊烷脒是替代甲氧苄啶-磺胺甲恶唑(TMP-SMX)的合理选择。